Development and Characterization of a Strain of Babesia gibsoni Resistant to Diminazene Aceturate in Vitro

概要

論文の詳細を見る
We attempted to develop a strain of Babesia gibsoni resistant to diminazene aceturate (DA), an anti-babesial drug, in vitro. Since the DA-sensitive B. gibsoni strain could survive and proliferate in culture medium containing 1 ng/ml DA, the concentration of DA was gradually increased from 1 ng/ml to 200 ng/ml. As a result, the parasites could survive and proliferate in the medium containing 200 ng/ml DA, which was much higher than the 50% inhibitory concentration (IC50) of DA for B. gibsoni. Subsequently, these parasites were removed from erythrocytes and exposed directly to 200 ng/ml DA. They could survive and invade fresh erythrocytes, though the DA-sensitive B. gibsoni strain could not survive. Based on those results, the parasites cultured within 200 ng/ml DA were determined to be a DA-resistant B. gibsoni strain. In addition, IC50 levels of clindamycin, doxycycline, and pentamidine for the DA-resistant B. gibsoni strain were determined. The IC50 levels of clindamycin, doxycycline and pentamidine for the DA-resistant strain were higher than those for the DA-sensitive strain. The IC50 of pentamidine for the resistant strain was much greater than that for the DA-sensitive strain. These results indicated that the DA-resistant B. gibsoni strain could have resistance not only to DA, but also to other anti-babesial drugs. In conclusion, we successfully developed a DA-resistant B. gibsoni strain in vitro.
社団法人　日本獣医学会の論文